Please assess the completion status of the following clinical trial:

Trial Title: A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is a healthy infant approximately 2 months of age~Exclusion Criteria:~* Birth mother is a known carrier of hepatitis B virus or another known carrier has lived in close contact with the participant~* Participant's birth mother did not receive any prenatal care~* Participant has previous history of hepatitis B infection~* Participant has been vaccinated against hepatitis B or birth mother was vaccinated within 6 months before birth of participant~* Participant has had a fever within 72 hours of study start~* Participant has received any blood-derived product or birth mother received blood-derived product within 6 months of birth of participant

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 2 Months
- Healthy Volunteers: t

Study Arms:
- Modified Process Hepatitis B vaccine 5 μg (Type: EXPERIMENTAL): Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.
- RECOMBIVAX HB™ Hepatitis B Vaccine (Type: ACTIVE_COMPARATOR): Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.
- Modified Process Hepatitis B vaccine 10 μg (Type: EXPERIMENTAL): Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.
- ENGERIX-B® (Type: ACTIVE_COMPARATOR): Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).